Markets
US-ECONOMY-BANK-RATE-MARKET
Members of the Fed Up Coalition (Nicholas Kamm/ Getty Images)

All these charts on the US job market are telling the Fed to cut rates

It’s not a bad time to be an American worker, by most metrics.

Luke Kawa
7/31/24 10:30AM

In deciding whether, when, and how much to cut rates, the Federal Reserve must judge whether the potential for inflation to re-accelerate is more likely, or would be more painful, than the risk of the labor market taking a nosedive.

Well, one thing that should be plainly clear based on data received this week is that the job market is cooling.

It’s not a bad time to be an American worker, judging by most of the metrics we use to measure the strength of the labor market through history. But it's simply getting less good. There's little threat of an inflationary spiral tied to too many workers making too much money buying too many things.

“With inflation trending down and labor markets showing slower growth and easing in level terms, there is little reason for the Fed not to begin an easing cycle in September,” writes Peter Williams, economist at 22V Research.

The ratio of job vacancies to the number of unemployed Americans is now below where it was in February 2020, just before mobility restrictions to limit the coronavirus’ spread became commonplace.

I’d take this metric with a heap of salt: for one, the longer an expansion goes, the more likely it is for job growth to come from people who weren't even looking for a job the previous month, rather than among the ranks of the unemployed. So empirically, the denominator isn’t a great measure of would-be potential workers. And job openings are not a top-tier gauge of how tight the labor market is because there’s not necessarily any kind of labor market change associated with adding a job posting. It’s like a costless call option an employer can use to try to find, or upgrade, their talent. Every business cycle, the ratio of job openings to unemployed makes higher highs. That suggests that either the labor market is getting structurally tighter, or businesses are simply posting more job openings than they actually need as time goes on.

Quitting your job, however, certainly speaks volumes. It’s generally something you only do when you a) have another opportunity lined up and b) that job pays better. Hiring, obviously, is another action that has an immediate imprint on the job market.

The private sector quits rate is 2.3%, well below its pre-pandemic level; the private sector hiring rate is closer to its 2020 trough than its February 2020 reading. This remains a very low-churn labor market, with the firing rate also extremely low. But the risk is that if economic growth decelerates further (which would seem to be more likely than not in the absence of rate cuts), the layoffs and discharge rate is more likely to go up than the hiring rate.

The quits rate tends to be a good leading or coincident indicator for wage growth. On Wednesday morning, the Employment Cost Index, considered by the US central bank to be the best quality gauge of wage pressures, showed the annual growth in private wages and salaries (excluding incentive-paid occupations) dipped to 4.1% in the second quarter, its slowest increase since 2021. 

One reason wage growth is elevated relative to pre-pandemic includes catch-up pay increases among unionized workers, per Cornell University assistant professor Justin Bloesch, something that happens with a lag versus changes in market compensation.

“Given the decline in quits, I suspect there is more room for compensation costs to slow in the quarters ahead,” writes Neil Dutta, head of US economics at Renaissance Macro Research. “The right tail for inflation has been clipped for the time being and the risks for both growth and inflation are skewed to the downside.”

And while perception may not always be reality, Americans’ attitudes on the state of the labor market have been deteriorating. The Conference Board’s “labor differential” shows the gap between the percent of those surveyed who say jobs are plentiful and those who think they’re hard to get. This metric, which often moves in the opposite direction as the unemployment rate, continues to sink lower.

More Markets

See all Markets
markets

Tesla jumps after Elon Musk discloses buying 2.57 million shares, worth more than $1 billion

Tesla soared in early trading on Monday after CEO Elon Musk disclosed a purchase of 2.57 million shares in the company, according to a new SEC filing.

Per the filing, the "Elon Musk Revocable Trust,” for which the Tesla and SpaceX chief is the trustee, reported acquiring 2.57 million shares, taking its total ownership to 413.36 million shares as of September 12, 2025. The block of equity was bought at prices ranging from $371.38 to $396.54.

Earlier this month, the board of directors proposed an eye-watering pay package that could award the tech billionaire up to $1 trillion, assuming that very ambitious market cap and fundamental milestones are met.

markets

Hims & Hers falls after FDA commissioner says its Super Bowl ad breached regulations

Hims & Hers is falling in premarket trading after its Super Bowl ad from February was singled out as the “most overt” example of “brazen” marketing tactics among online pharmacies by FDA Commissioner Marty Makary.

The claim, made in an opinion piece written by Makary and published in the JAMA Network on Friday, highlighted the agency’s stricter enforcement policies on pharmaceutical advertisements.

“Equally brazen, online pharmacies are advertising drugs with only upsides mentioned, contributing to America’s culture of overreliance on pharmaceuticals for health,” wrote Makary. “This breach of FDA regulation was most overt earlier this year when Hims & Hers ran a Super Bowl ad highlighting the benefits of glucagon-like peptide-1 drugs without any mention of side effects or disclaimers.”

Hims’ Super Bowl ad touted its direct-to-consumer weight loss medications as “life-changing,” “affordable,” and “doctor-trusted,” billing its approach as “the future of healthcare.”

Google searches for the company spiked after the ad appeared during The Big Game.

Last week, President Donald Trump issued an executive order directing the Secretary of Health and Human Services to crack down on TV drug ads. It was initially unclear whether that order applied to telehealth companies.

Compounded drugs aren’t subject to the same regulatory burdens over their advertisements as branded, FDA-approved drugs made by pharmaceutical companies. For example, Hims can advertise generic Prozac for climax control (an off-label use) while the company that made the drug, Eli Lilly, cannot.

markets

Nvidia falls after Chinese regulator said it violated the country’s antitrust laws in 2020 deal

Nvidia dropped as much as 2.9% in early trading on Monday after China's State Administration for Market Regulation ruled that the chipmaker violated the country's antitrust laws after acquiring Mellanox Technologies, an Israeli-American network solutions supplier.

In 2020, Beijing approved Nvidia's ~$7 billion acquisition under the condition that the chipmaker would not discriminate against Chinese companies. Since then, Nvidia has had to redesign its chips to comply with the US government's regulations that temporarily banned the company from selling its advanced chips, including the H100.

Monday's preliminary finding from the SAMR comes amidst ongoing trade talks between US and Chinese officials in Madrid, with the tariff truce between the world's two largest economies set to expire in November.

As Sherwood’s Luke Kawa noted in August, China has appeared determined to “wean itself off of any dependence on Nvidia and US technology to develop its AI capabilities.”

According to Reuters, under Chinese antitrust law, companies can “face fines of between 1% and 10% of their annual sales from the previous year.” Nvidia’s sales in China generated $17.1 billion of revenue in its most recent fiscal year. Assuming the maximum penalty, the impact would be ~$1.7 billion, less than 1% of Wall Street’s forecast for Nvidia’s total revenue this fiscal year.

markets

Rocket lab soars to new record close amid rally for retail faves

Rocket Lab ripped by roughly 10% Friday to close at a new all-time high, riding an upturn of retail enthusiasm for a coterie of tech-themed favorites, even as the broader market was more or less flat on the day.

Goldman Sachs’ basket of “retail favorites” — its heaviest weights are Reddit, AppLovin, and Tempus AI — was the second-biggest gainer among the company’s flagship US equity baskets on Friday, rising about 1.6%. The S&P was almost dead flat.

It’s not Rocket Lab’s first retail rodeo, as the money-losing company has more than doubled this year and is up nearly 700% over the last 12 months.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.